About Glaukos Corporation

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

CEO

Thomas Burns

Employees

653

Headquarters

229 Avenida Fabricante
San Clemente, California 92672-7531
Phone: 19493679600
www.glaukos.com

News

Glaukos: Show Me The Money (NYSE:GKOS)
Nov 10, 2022 15:00pm

Glaukos shares fall post Q3 earnings announcement despite top-line guidance hike. Click here to read my analysis of GKOS stock.

Source:Seeking Alpha

Glaukos Announces Participation in the Stephens Annual Investment Conference
Nov 07, 2022 12:00pm

Source:Kwhen Finance

Glaukos Corp Earnings Miss, Revenue Beats In Q3 By Investing.com
Nov 05, 2022 04:05am

Glaukos Corp Earnings Miss, Revenue Beats In Q3

Source:Investing.com

Glaukos Corporation (GKOS) Q3 2022 Earnings Call Transcript
Nov 05, 2022 02:26am

Glaukos Corporation (NYSE:NYSE:GKOS) Q3 2022 Earnings Conference Call November 02, 2022 04:30 PM ET Company Participants Chris Lewis - Vice President-Investor Relations & Corporate…

Source:Seeking Alpha

Glaukos Corporation Announces Third Quarter 2022 Financial Results
Nov 02, 2022 20:05pm

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2022. Key highlights include: Net sales of $71.3 million in Q3 2022. Glaucoma net sales of $53.7 million and Corneal Health net sales of $17.5 million in Q3 2022. Gross margin of approximately

Source:Business Wire

Stephens Resumes Glaukos Corporation at Overweight
Oct 13, 2022 20:29pm

https://www.investing.com/news/pro/stephens-resumes-glaukos-corporation-at-overweight-432SI-2911944

Source:Investing.com

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting
Sep 28, 2022 11:00am

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held September 30 - October 3, 2022 in Chicago,

Source:Wallstreet:Online